SynthesisBMC gastroenterology2018

Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer.

Liuting Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.